A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

To be part of this study, you must have a specific type of head and neck cancer known as 'squamous cell carcinoma.' This cancer needs to be in certain areas like the throat, voice box, or inside of the mouth, and it should be 'locally advanced,' meaning it hasn't spread to other parts of your body. Importantly, the hospital doctors must have confirmed that your cancer could not be removed by surgery.

You also need to have already finished your main treatment for this cancer, which involved a combination of chemotherapy and radiotherapy at the same time. The goal of that treatment would have been to cure your cancer, and your cancer should not have gotten worse since then.

There are also reasons why you might not be able to join. For example, if your head and neck cancer started in other areas not listed, or if you had more than one main cancer. You also can't join if your cancer was removed by surgery before your chemotherapy and radiotherapy, or if your cancer has come back or was only treated with radiotherapy alone.

If you decide to join this study, you would first go through some checks to make sure you're eligible. If you are, you would then start receiving the study medicine, volrustomig, or be in the observation group. This medicine is given as a drip into your arm (intravenous infusion). The study involves regular visits to the clinic for assessments, which will include blood tests, scans, and physical examinations to see how you are responding to the treatment and to check for any side effects. You will be closely monitored by the study team. The total duration of your participation in the study, including the treatment and follow-up period, will be explained in detail by the study doctor.